Findings reveal increased mortality risk linked to high lactate dehydrogenase and clinical characteristics in dermatomyositis.
Objective This study aims to evaluate the clinical characteristics and prognostic significance of serum lactate dehydrogenase (LDH) in patients with anti-MDA5+ dermatomyositis (anti-MDA5+ DM). Methods We assessed 246 consecutive patients with anti-MDA5+ DM. The patients were divided into two groups based on LDH levels: the LDH ≤ 338 U/L group and the LDH > 338 U/L group. We compared the clinical characteristics, laboratory findings, and long-term prognosis between the two groups. Results Overall, the one-year mortality rate in patients with anti-MDA5+ DM was high, at 24.39% (60/246). LDH levels exhibited a nonlinear, inverted S-shaped relationship with the overall mortality risk in anti-MDA5+ DM patients (nonlinear P = 0.001). Patients in the LDH > 338 U/L group had significantly higher levels of ALT [64.0 (32.0, 121.0) vs 40.0 (23.0, 66.5), P<0.001], AST [75.0 (47.5, 134.0) vs 40.0 (26.0, 60.6), P<0.001], CK [107.0 (42.0, 208.8) vs 50.0 (35.5, 100.5), P<0.001], CRP [8.5 (3.5, 17.6) vs 4.7 (2.7, 10.2), P<0.001], and serum ferritin levels [1307.6 (679.8, 1565.5) vs 1001.0 (391.2, 1307.6), P<0.001] compared to the LDH ≤ 338 U/L group. Additionally, the positivity rate of Anti-Ro52 antibodies (70.7% vs 57.7%, P = 0.033), the incidence of rapidly progressive interstitial lung disease (RPILD) (42.3% vs 29.3%, P = 0.033), and the mortality rate (35.0% vs 13.8%, P<0.001) were significantly higher in the LDH > 338 U/L group than in the LDH ≤ 338 U/L group. Multivariable regression analysis revealed that LDH > 338 U/L and the presence of RPILD were associated with poor prognosis [hazard ratios of 2.253 (95% CI 1.258, 4.035, P = 0.006) and 10.293 (95% CI 4.683, 22.623, P < 0.001), respectively]. Conclusion Patients with different LDH levels exhibit distinct clinical characteristics, laboratory findings, and long-term prognosis. Elevated LDH levels (> 338 U/L) and the presence of RPILD are associated with poor prognosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: